Post-marketing Study of Monteplase ("Cleactor") in Patients With Acute Pulmonary Embolism
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 75 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
1) Patients who consent for study participation and submit written informed consent with free will by patient or legally authorized representative.
2) Patients aged between 20 years or above and under 75 years old at the time of obtaining informed consent.
3) Patients with acute pulmonary embolism within 5 days after the onset.
4) Patients with acute pulmonary embolism with hemodynamic instability and fulfill all of the following 4 items:
Confirmed to have thrombi, emboli, or disorders in pulmonary circulation detected by pulmonary angiography or computed tomography.
Confirmed to have any of the following right ventricular overloads by echocardiography:
i) Dilation of right ventricular cavity or hypokinesis in ventricular wall
ii) Floating thrombi in pulmonary artery and right heart
iii) Paradoxical motion in the interventricular septum
iv) Disparity of tricuspid regurgitation pressure
v) Enlargement of pulmonary artery
Mean pulmonary arterial pressure (PAP) is 20 mmHg or above
PaO2 is 65 mmHg or below (confirmed by blood gas analysis)
Patients with concurrent hemorrhage (e.g., gastrointestinal bleeding, urinary tract bleeding, retroperitoneal bleeding, intracranial bleeding, or hemoptysis).
Patients who underwent intracranial or spinal operation or injury within 2 months prior to study treatment.
Patients with intracranial tumor, arteriovenous malformation, or aneurysm
Patients with hemorrhagic diathesis (e.g., vascular purpura, thrombocytopenia, hemophilia)
Patients with hypertension of systolic blood pressure >=180 mmHg or diastolic pressure >= 110 mmHg.
Patients with a history of cerebrovascular disorder (e.g., cerebral infarction, intracerebral hemorrhage).
Patients with severe hepatic disorder (e.g., cirrhosis, severe hepatitis) or severe renal disorder (e.g., renal failure).
Patients received thrombolytic drug (t-PA or urokinase) within 7 days prior to study treatment.
Patients with pulmonary cardiac arrest (CPA).
Patients with a history of hypersensitivity to monteplase or protein preparations.
Pregnant women, women suspected of being pregnant, women who desire to become pregnant during a period between obtaining informed consent to the final observation, or lactating women.
Patients who are judged to be ineligible for study entry by the investigator or subinvestigator.